Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease
NCT03564964
·
clinicaltrials.gov ↗
NO_LONGER_AVAILABLE
Status
INDUSTRY
Sponsor class
Conditions
Alzheimer Disease
Dementia
Cognition Disorders
Interventions
DRUG:
SUVN-502
Sponsor
Suven Life Sciences Limited